当前位置: X-MOL 学术Circulation › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
International Expert Consensus on Switching Platelet P2Y12 Receptor–Inhibiting Therapies
Circulation ( IF 37.8 ) Pub Date : 2017-11-14 , DOI: 10.1161/circulationaha.117.031164
Dominick J. Angiolillo 1 , Fabiana Rollini 1 , Robert F. Storey 2 , Deepak L. Bhatt 3 , Stefan James 4 , David J. Schneider 5 , Dirk Sibbing 6, 7 , Derek Y.F. So 8 , Dietmar Trenk 9 , Dimitrios Alexopoulos 10 , Paul A. Gurbel 11 , Willibald Hochholzer 9 , Leonardo De Luca 12, 13, 14 , Laurent Bonello 15 , Daniel Aradi 16 , Thomas Cuisset 17 , Udaya S. Tantry 11 , Tracy Y. Wang 18 , Marco Valgimigli 19 , Ron Waksman 20 , Roxana Mehran 21 , Gilles Montalescot 22 , Francesco Franchi 1 , Matthew J. Price 23
Affiliation  

Dual antiplatelet therapy with aspirin and a P2Y12 inhibitor is the treatment of choice for the prevention of atherothrombotic events in patients with acute coronary syndromes and for those undergoing percutaneous coronary interventions. The availability of different oral P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor) has enabled physicians to contemplate switching among therapies because of specific clinical scenarios. The recent introduction of an intravenous P2Y12 inhibitor (cangrelor) further adds to the multitude of modalities and settings in which switching therapies may occur. In clinical practice, it is not uncommon to switch P2Y12 inhibitor, and switching may be attributed to a variety of factors. However, concerns about the safety of switching between these agents have emerged. Practice guidelines have not fully elaborated on how to switch therapies, leaving clinicians with limited guidance on when and how to switch therapies when needed. This prompted the development of this expert consensus document by key leaders from North America and Europe with expertise in basic, translational, and clinical sciences in the field of antiplatelet therapy. This expert consensus provides an overview of the pharmacology of P2Y12 inhibitors, different modalities and definitions of switching, and available literature and recommendations for switching between P2Y12 inhibitors.


中文翻译:

转换血小板P2Y 12受体抑制疗法的国际专家共识

阿司匹林和P2Y 12抑制剂双重抗血小板治疗是预防急性冠状动脉综合征和经皮冠状动脉介入治疗的患者发生动脉粥样硬化血栓形成事件的首选治疗方法。由于特定的临床情况,不同口服P2Y 12抑制剂(氯吡格雷,普拉格雷,替卡格雷)的可用性使医生能够考虑在疗法之间进行切换。最近引入的静脉内P2Y 12抑制剂(坎格雷洛)进一步增加了转换治疗可能发生的多种方式和设置。在临床实践中,切换P2Y 12并不少见抑制,转换可能归因于多种因素。然而,已经出现了关于在这些代理之间切换的安全性的担忧。关于如何转换治疗方法的实践指南尚未完全阐明,使临床医生对何时以及何时需要何时转换治疗方法的指导有限。这促使北美和欧洲的主要领导者开发了该专家共识性文件,他们在抗血小板治疗领域具有基础,转化和临床科学方面的专业知识。该专家共识概述了P2Y 12抑制剂的药理作用,不同的切换方式和定义,以及有关P2Y 12抑制剂之间切换的可用文献和建议。
更新日期:2017-11-14
down
wechat
bug